

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

NCT07263204

Status RECRUITING
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment 15,000 participants

Key Eligibility Criteria

Inclusion (4)

- Adults aged \geq 18 years.
- HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the 2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults.
- HCM phenocopy cohort: Adults with an LV wall thickness \geq 13 mm at any site on echocardiography.
- Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.

Exclusion (1)

- Patients from whom analyzable ECG data cannot be obtained.

Locations (1 total)

Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China